Back to search

France· FR:65505616

ELAHERE 5 mg/mL, solution à diluer pour perfusion

A mirvetuximab soravtansine product containing mirvétuximab soravtansine, registered in France by ABBVIE DEUTSCHLAND (ALLEMAGNE). The same ATC class is registered in 13 of our 19 countries.

ATC L01FX26

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedELAHERE 5 mg/mL, solution à diluer po…ATCL01FX26REGISTER NO.FR:65505616PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Mirvetuximab soravtansine is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FX26 (mirvetuximab soravtansine), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Mirvetuximab soravtansine · ATC L01FX26

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
MIRVÉTUXIMAB SORAVTANSINE
Manufacturer
ABBVIE DEUTSCHLAND (ALLEMAGNE)
Country
France (FR)
ATC code
L01FX26
ATC class
Mirvetuximab soravtansine
Defined daily dose
18 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955104582
    1 flacon en verre de 20 mL

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mirvetuximab soravtansine in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mirvetuximab soravtansine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Elahere
  • Iceland · Elahere
  • Liechtenstein · Elahere
  • Norway · Elahere

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c1ba0863-d6ab-4cfd-824e-4aa6e11bad20
GET /v1/drugs/c1ba0863-d6ab-4cfd-824e-4aa6e11bad20?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65505616",
  "date_amm": "2024-11-14",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/24/1866",
  "substance": "MIRVÉTUXIMAB SORAVTANSINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about mirvetuximab soravtansine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.